Tallman MS, Gilliland G, Rowe JM. Drug therapy for acute myeloid leukemia. Blood. 2005;106:1154-1163. Abstract
Juliusson G, Antunovic P, Derolfet A, et al. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood. 2009;113:4179-4187. Abstract
Dohner H, Estey EH, Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010;115:453-474. Abstract
Löwenberg B, Ossenkoppele GJ, van Putten W, et al. High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med. 2009;361:1235-1248. Abstract
Castaigne S, Pautas C, Terre C, et al. Fractionated doses of gemtuzumab ozogamicin (GO) combined to standard chemotherapy (CT) improve event-free and overall survival in newly-diagnosed de novo AML patients aged 50-70 years old: a prospective randomized phase 3 trial from the Acute Leukemia French Association (ALFA). In: Proceedings from the American Society of Hematology; December 10-13, 2011; San Diego, CA. Abstract 6.
Burnett AK, Russell NH, Hills RK, et al. Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia. J Clin Oncol. 2012;30:3924-3931. Abstract
Cashen AF, Schiller GJ, O'Donnell MR, DiPersio JF. Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia. J Clin Oncol. 2010;28:556-561. Abstract
Kantarjian HM, Thomas XG, Dmoszynska A, et al. Multicenter, randomized, open-label, phase iii trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients. J Clin Oncol. 2012;30:2670-2677. Abstract
Blum W, Garzona R, Klisovica RB, et al. Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine. Proc Natl Acad Sci U S A. 2010;107:7473-7478. Abstract
Ritchie EK, Feldman EJ, Christos PJ, et al. Decitabine in patients with newly diagnosed and relapsed acute myeloid leukemia. Leuk Lymphoma. 2013. [Epub ahead of print] Abstract
Roboz GJ. Novel approaches to the treatment of acute myeloid leukemia. Hematology Am Soc Hematol Educ Program. 2011;2011:43-50. Abstract
Walter RB, Golley TA, Wood BL, et al. Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia. J Clin Oncol. 2011;29:1190-1197. Abstract
van Rahenen A, Feller N, Kelder A, et al. High stem cell frequency in acute myeloid leukemia at diagnosis predicts high minimal residual disease and poor survival. Clin Cancer Res. 2005;11:6520-6527. Abstract
Guzman ML, Neering SJ, Upchurch D, et al. Nuclear factor-?B is constitutively activated in primitive human acute myelogenous leukemia cells. Blood. 2001;98:2301-2307. Abstract
Burnett AK, Russell NH, McMullin MF, et al. A randomised comparison of clofarabine versus low dose ara-c as first line treatment for older patients with AML. In: Proceedings from the American Society of Hematology; December 8-11, 2012; Atlanta, GA. Abstract 889.
Reiffers J, Stoppa AM, Attal M, et al. Allogeneic vs autologous stem cell transplantation vs chemotherapy in patients with acute myeloid leukemia in first remission: the BGMT 87 study. Leukemia. 199610:1874-1882. Abstract
Appelbaum FR, Barrall J, Storb R, et al. Bone marrow transplantation for patients with myelodysplasia. Ann Intern Med. 1990;112:590-597. Abstract
Runde V, de Witte T, Arnold R, et al. Bone marrow transplantation from HLA-identical siblings as first-line treatment in patients with myelodysplastic syndromes: early transplantation is associated with improved outcome. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 1998;21:255-261. Abstract
Gyurkocza B, Storb R, Storeret BE, al. Nonmyeloablative allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia. J Clin Oncol. 2010;28:2859-2867. Abstract
McClune BL, Weisdorf DJ, Pedersen TL, et al. Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome. J Clin Oncol. 2010;28:1878-1887. Abstract
Kurosawa S, Yamaguchi T, Uchida N, et al. Comparison of allogeneic hematopoietic cell transplantation and chemotherapy in elderly patients with non-M3 acute myelogenous leukemia in first complete remission. Biol Blood Marrow Transplant. 2011;17:401-411. Abstract
Farag SS, Maharry K, Zhang M-J, et al. Comparison of reduced-intensity hematopoietic cell transplantation with chemotherapy in patients age 60-70 years with acute myelogenous leukemia in first remission. Biol Blood Marrow Transplant. 2001;19:1796-1803. Abstract
Estey E, de Lima M, Tibes R, et al. Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). Blood. 2007;109:1395-1400. Abstract
Sandhu R, Petersdorf S, Sandmaier BM, et al. Frequency of allogeneic stem cell transplant (SCT) in patients presenting with newly-diagnosed AML or AML at time of first salvage therapy. Blood. 2009;114:Abstract 4332
Saber W, Opie S, Rizzo JD, Zhang M-J, Horowitz MM, Schriber J. Outcomes after matched unrelated donor versus identical sibling hematopoietic cell transplantation in adults with acute myelogenous leukemia. Blood. 2012;119:3908-3916. Abstract
Brunstein CG, Eapen M, Ahn KW, et al. Reduced-intensity conditioning transplantation in acute leukemia: the effect of source of unrelated donor stem cells on outcomes. Blood. 2012;119:5591-5598. Abstract
Gerds AT, Appelbaum FR. To transplant or not to transplant for adult acute myeloid leukemia: an ever-evolving decision. Clin Adv Hematol Oncol. 2012;10:655-662. Abstract
Othus M, Kantarjian HM, Petersdorf S, et al. Declining rates of treatment-related mortality in patients with newly diagnosed acute myeloid leukemia (AML) given "intensive" induction regimens: a report from the Southwest Oncology Group (SWOG) and MD Anderson Cancer Center (MDA). In: Proceedings from the American Society of Hematology; December 8-11, 2012; Atlanta, GA. Abstract 129.
Gooley TA, Chien JW, Pergam SA, et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med. 2010;363:2091-2101. Abstract
Craddock C, Labopin M, Pillai S, et al. Factors predicting outcome after unrelated donor stem cell transplantation in primary refractory acute myeloid leukaemia. Leukemia. 2011;25:808-813. Abstract
Armand P, Gibson CJ, Cutler C, et al. A disease risk index for patients undergoing allogeneic stem cell transplantation. Blood. 2012 120: 905-913. Abstract
Walter RB, Othus M, Borthakur G, et al. Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment. J Clin Oncol. 2011;29:4417-4423. Abstract
Sorror ML, Giralt S, Sandmaier BM, et al. Hematopoietic cell transplantation-specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences. Blood. 2007;110:4606-4613. Abstract
Sorror M, Storer B, Sandmaier BM, et al. Hematopoietic cell transplantation-comorbidity index and Karnofsky Performance Status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantation. Cancer. 2008;112:1992-2001. Abstract
Ostronoff F, Storer B, Storb R, et al. Interaction of age and comorbidities and their impacts on hematopoietic cell transplantation (HCT) outcomes. In: Proceedings from the American Society of Hematology; December 10-13, 2011; San Diego, CA. Abstract 665.
Sorror ML, Sandmaier BM, Storer BE, et al. Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies. JAMA. 2011;306:1874-1883. Abstract
National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: Myelodysplastic syndromes. Version 2.2013.
Steensma DP, Stone RM. Lenalidomide in AML: Del(5q) or who? Blood. 2011;118:481-482. Abstract
Ito T, Ando H, Suzuki T, et al. Identification of a primary target of thalidomide teratogenicity. Science. 2010;327:1345-1350. Abstract
Zhu YX, Kortuem KM, Stewart AK. Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma. Leuk Lymphoma. 2013;54:683-687. Abstract
Figueroa ME, Skrabanek L, Li Y, et al. MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation. Blood. 2009;114:3448-3458. Abstract
Shen L, Kantarjian H, Guo Y, et al. DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes. J Clin Oncol. 2009;28:605-613. Abstract
Fandy TE, Herman JG, Kerns P, et al. Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies. Blood. 2009;114:2764-2773. Abstract
Goodyear OC, Dennis M, Jilani NY, et al. Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML). Blood. 2012;119:3361-3369. Abstract
Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;210:2454-2465. Abstract
Bejar R, Stevenson K, Abdel-Wahab O, et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med. 2011;364:2496-506. Abstract
Walter MJ, Shen D, Ding L, et el. Clonal architecture of secondary acute myeloid leukemia. N Engl J Med. 2012;366:1090-1098. Abstract
Sekeres MA, Maciejewski JP, Giagounidis AA, et al. Relationship of treatment-related cytopenias and response to lenalidomide in patients with lower-risk myelodysplastic syndromes. J Clin Oncol. 2008;26:5943-5949. Abstract
Itzykson R, Kosmider O, Cluzeau T, et al. Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias. Leukemia. 2011;25:1147-1152. Abstract
Sekeres MA, Komrokji RS, Lancet JE, et al. Final results from the phase 2 continuation study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes (MDS). In: Proceedings from the American Society of Hematology; December 10-13, 2011; San Diego, CA. Abstract 607.
Ma X, Does M, Raza A, Mayne ST. Myelodysplastic syndromes: incidence and survival in the United States. Cancer. 2007;109:1536-1542. Abstract
Cutler CS, Lee SJ, Greenberg P, et al. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood. 2004;104:579-585. Abstract
Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol. 2002;20:2429-2440. Abstract
Jabbour E, Garcia-Manero G, Batty N, et al. Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy. Cancer. 116:3830-3834. Abstract
Prébet T, Gore SD, Esterni B, et al. Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure. J Clin Oncol. 2011;29:3322-3327. Abstract
Sorror ML, Maris MB, Storb R, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106:2912-2919. Abstract
Pullarkat V, Blanchard S, Tegtmeier B, et al. Iron overload adversely affects outcome of allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2008;42:799-805. Abstract
Pasquini MC, Wang Z. Current use and outcome of hematopoietic stem cell transplantation: CIBMTR Summary Slides, 2012. Available at: http://www.cibmtr.org. Accessed April 25, 2013.
Nakamura R, Palmer JM, O'Donnell MR, et al. Reduced intensity allogeneic hematopoietic stem cell transplantation for MDS using tacrolimus/sirolimus-based GVHD prophylaxis. Leuk Res. 2012;36:1152-1156. Abstract
Krishnan A, Bhatia S, Slovak ML, et al. Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: an assessment of risk factors. Blood. 2000;95:1588-1593. Abstract
Grover RS, Pullarkat V, Sun C-L, Bhatia S, Forman SJ. Therapy-related myelodysplasia/acute myeloid leukemia (t-MDS/AML) after conventionally-treated breast cancer: impact of cytogenetics on outcome after allogeneic hematopoietic cell transplantation (HCT). In: Proceedings from the American Society of Hematology; December 10-13, 2011; San Diego, CA. Abstract 4149.
Schwind S, Marcucci G, Kohlschmidt J, et al. Low expression of MN1 associates with better treatment response in older patients with de novo cytogenetically normal acute myeloid leukemia. Blood. 2011;118:4188-4198. Abstract
Blum W, Garzon R, Klisovic RB, et al. Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine. Proc Natl Acad Sci U S A. 2010;107:7473-7478. Abstract
Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10:223-232. Abstract
Fenaux P, Mufti GJ, Hellström-Lindberg E, et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol. 2010;28:521-523. Abstract
Choi SH, Byun HM, Kwan JM, Issa JP, Yang AS. Hydroxycarbamide in combination with azacitidine or decitabine is antagonistic on DNA methylation inhibition. Br J Haematol. 2007;138:616-623. Abstract
Garcia-Manero G, Shan J, Faderl S, et al. A prognostic score for patients with lower risk myelodysplastic syndrome. Leukemia. 2008;22:538-543. Abstract
Bejar R, Stevenson KE, Caughey BA, et al. Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes. J Clin Oncol. 2012;30:3376-3382. Abstract
Anderson JE, Gooley TA, Schoch G, et al. Stem cell transplantation for secondary acute myeloid leukemia: evaluation of transplantation as initial therapy or following induction chemotherapy. Blood. 1997;89:2578-2585. Abstract
National Institutes of Health. Studies on CPX-351. http://clinicaltrials.gov/ct2/results?term=cpx-351. Accessed May 2, 2013.
National Institutes of Health. Studies on elacytarabine. http://clinicaltrials.gov/ct2/results?term=elacytarabine. Accessed May 2, 2013.
National Institutes of Health. Studies on vosaroxin. http://clinicaltrials.gov/ct2/results?term=vosaroxin. Accessed May 2, 2013.
National Institutes of Health. Study on clofarabine or daunorubicin hydrochloride and cytarabine followed by decitabine or observation in treating older patients with newly diagnosed acute myeloid leukemia. http://clinicaltrials.gov/show/NCT01041703. Accessed May 2, 2013.
National Institutes of Health. Studies on idarubicin and vorinostat. http://clinicaltrials.gov/ct2/results?term=idarubicin+vorinostat. Accessed May 2, 2013.
Hellström-Lindberg E, Negrin R, Stein R, et al. Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model. Br J Haematol. 1997;99:344-351. Abstract
National Institutes of Health. Study of sapacitabine in acute myeloid leukemia (AML). http://www.clinicaltrials.gov/ct2/show/NCT01211457?term=Sapacitabine&rank=2 Accessed May 2, 2013.
Garcia-Manero G. New MDS strategies. Presented at: Hematologic Malignancies 2012; October 10-14, 2012; Houston, Texas.
Kantarjian H, Faderl S, Garcia-Manero G, et al. Oral sapacitabine for the treatment of acute myeloid leukaemia in elderly patients: a randomised phase 2 study. Lancet Oncol. 2012;13:1096-1104. Abstract
National Institutes of Health. A study of ARRY-614 in patients with low or intermediate-1 risk myelodysplastic syndrome. http://www.clinicaltrials.gov/ct2/show/NCT00916227?term=ARRY-614&rank=2. Accessed May 2, 2013.
National Institutes of Health. Studies of ezatiostat. http://www.clinicaltrials.gov/ct2/results?term=Ezatiostat&Search=Search. Accessed May 2, 2013.

CME

Acute Myeloid Leukemia and Myelodysplastic Syndromes in Older Patients

Authors: Frederick R. Appelbaum, MD; Stephen J. Forman, MD; Gail J. Roboz, MD; David Steensma, MD; Willis Navarro, MD
CME Released: 5/21/2013; Reviewed and Renewed: 9/23/2014
THIS ACTIVITY HAS EXPIRED FOR CREDIT
Valid for credit through: 9/23/2015, 11:59 PM EST

Target Audience and Goal Statement

This activity is intended for hematologists, oncologists, and other healthcare professionals who treat patients with myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML).

The goal of this activity is to discuss the latest approaches to the treatment of older patients with MDS and AML.

Upon completion of this activity, participants will be able to:

Identify disease- and patient-related factors that predict outcomes of hematopoietic cell transplantation (HCT), new drugs, or combination therapy in older patients with MDS and AML
Explain recent clinical trial results that have influenced the selection of patients for treatment of MDS and AML
Compare the risks and benefits of treatment options and how timing of therapy choices affects outcomes
Describe appropriate candidates for a prospective study on outcomes of HCT in adults 65 years of age and older with MDS

Disclosures

As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.

Author(s)

Frederick R. Appelbaum, MD

Executive Director, Seattle Cancer Care Alliance; Director, Fred Hutchinson Cancer Research Center; Professor, University of Washington School of Medicine, Seattle, Washington

Disclosures

Disclosure: Frederick R. Appelbam, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Celator Pharmaceuticals, Inc.; Pfizer Inc; Igenica, Inc.; Abbott Laboratories

Dr Appelbaum does intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr Appelbaum does intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Stephen J. Forman, MD

Francis and Kathleen McNamara Distinguished Chair in Hematology and Hematopoietic Cell Transplantation; Clinical Director, Cancer Immunotherapeutics & Tumor Immunology, City of Hope, Duarte, California

Disclosures

Disclosure: Stephen J. Forman, MD, has disclosed no relevant financial relationships.

Dr Forman does intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr Forman does intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Gail J. Roboz, MD

Director, Leukemia Program; Associate Professor of Medicine, Weill Medical College, Cornell University, New York, New York

Disclosures

Disclosure: Gail J. Roboz, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Celgene Corporation

Dr Roboz does intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr Roboz does intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

David Steensma, MD

Associate Professor of Medicine, Harvard Medical School; Adult Leukemia Program, Dana-Farber Cancer Institute; Hematological Oncology Service, Brigham & Women’s Hospital, Boston, Massachusetts

Disclosures

Disclosure: David Steensma, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Genoptix, Inc.; Celgene Corporation; Novartis Pharmaceuticals Corporation; Amgen Inc.

Dr Steensma does intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr Steensma does intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States

Willis Navarro, MD

Vice President, Transplant Medical Services, National Marrow Donor Program®/Be The Match®, Minneapolis, Minnesota

Current position: Vice President of Clinical Research and Development at Atara Biotherapeutics and Associate Clinical Professor of Medicine at the University of California, San Francisco

Disclosures

Disclosure: Willis Navarro, MD, has disclosed no relevant financial relationships.

Dr Navarro does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr Navarro does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Editor(s)

Charlotte Warren

Scientific Director, Medscape, LLC

Disclosures

Disclosure: Charlotte Warren has disclosed no relevant financial relationships.

Ellyce Hayes

Strategic Marketing Specialist, National Marrow Donor Program®/Be The Match®, Minneapolis, Minnesota

Disclosures

Disclosure: Ellyce Hayes has disclosed no relevant financial relationships.

Alissa Salvato

Medical Education Outreach Specialist, National Marrow Donor Program®/Be The Match®, Minneapolis, Minnesota

Disclosures

Disclosure: Alissa Salvato has disclosed no relevant financial relationships.

Tim Walker

Medical Writer, National Marrow Donor Program®/Be The Match®, Minneapolis, Minnesota

Disclosures

Disclosure: Tim Walker has disclosed no relevant financial relationships.

CME Reviewer(s)

Nafeez Zawahir, MD

CME Clinical Director, Medscape, LLC

Disclosures

Disclosure: Nafeez Zawahir, MD, has disclosed no relevant financial relationships.

Accreditation Statements

For Physicians

Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Medscape, LLC designates this enduring material for a maximum of 2.25 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Medscape, LLC staff have disclosed that they have no relevant financial relationships.

Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

Read the target audience, learning objectives, and author disclosures.
Study the educational content online or printed out.
Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

From Medscape Education Oncology

CME

Acute Myeloid Leukemia and Myelodysplastic Syndromes in Older Patients

Authors: Frederick R. Appelbaum, MD; Stephen J. Forman, MD; Gail J. Roboz, MD; David Steensma, MD; Willis Navarro, MDFaculty and Disclosures

THIS ACTIVITY HAS EXPIRED FOR CREDIT

CME Released: 5/21/2013; Reviewed and Renewed: 9/23/2014

Valid for credit through: 9/23/2015, 11:59 PM EST

processing....

Abbreviations

AA = aplastic anemia
ALL = acute lymphoblastic leukemia
ALLIANCE trial = Alliance for Clinical Trials in Oncology
AML = acute myeloid leukemia
ASH = American Society of Hematology
ATG = antithymocyte globulin
ATRA = all-trans-retinoic acid
CALGB = Cancer and Leukemia Group B
CBF = core-binding factor
CEBPA = CCAAT/enhancer binding protein-alpha
CIBMTR = Center for International Blood and Marrow Transplant Research
CMML = chronic myelomonocytic leukemia
CR = complete remission
CRBN = cereblon
DA = daunorubicin + cytarabine
DACi = deacetylase activity inhibitor
AGO = daunorubicin + cytarabine + gemtuzumab
DNMT3A = DNA methyltransferase 3A
DNR = daunorubicin
DFS = disease-free survival
ECOG = European Cooperative Oncology Group
EFS = event-free survival
ESA = erythropoiesis-stimulating agent
FDA = US Food and Drug Administration
G-CSF = granulocyte-colony stimulating factor
FHCRC = Fred Hutchinson Cancer Research Center
FLT3 = FMS-like tyrosine kinase 3
GVHD = graft-versus-host disease
HCT = hematopoietic cell transplantation
HCT-CI = hematopoietic cell transplantation comorbidity index
HLA = human leukocyte antigen
HMA = hypomethylating agent
IL-3 = interleukin 3
IMiDs = immunomodulatory derivatives
IPSS = International Prognostic Scoring System
JAK-2 = Janus tyrosine kinase 2
JCO = Journal of Clinical Oncology
LD = low-dose
LDAC = low-dose cytosine arabinoside (Ara-C)
LGL = large granular lymphocyte
MAP kinase = mitogen-activated protein kinase
MCV = mean corpuscular volume
MDA = MD Anderson Cancer Center
MDACC = MD Anderson Cancer Cancer
MDS = myelodysplastic syndromes
MPD = myeloproliferative disease
MRC = Medical Research Council
MRD = minimal residual disease
NCCN = National Comprehensive Cancer Network
NIH = National Institutes of Health
NK cells = natural killer cells
NMDP = National Marrow Donor Program®
ORR = overall response rate
OS = overall survival
PRCA = pure red cell aplasia
RARS = refractory anemia with ring sideroblasts
RBC = red blood cell
RFS = relapse-free survival
RIC = reduced-intensity conditioning (regimen)
SC = supportive care
SWOG = formerly the Southwest Oncology Group
TET2 = Ten-Eleven-Translocation-2
TNFα = tumor necrosis factor alpha
TRM = transplant-related mortality (risk score)
VEGF = vascular endothelial growth factor
WBC = white blood cell count
WHO = World Health Organization
WPSS = WHO classification-based Prognostic Scoring System

« Return to: Acute Myeloid Leukemia and Myelodysplastic Syndromes in Older Patients

CME Information Download Slides

Print
Like Tweet

References

Faculty and Disclosures

Author(s)

Frederick R. Appelbaum, MD

Stephen J. Forman, MD

Gail J. Roboz, MD

David Steensma, MD

Willis Navarro, MD

Editor(s)

Charlotte Warren

Ellyce Hayes

Alissa Salvato

Tim Walker

CME Reviewer(s)

Nafeez Zawahir, MD

CME

Acute Myeloid Leukemia and Myelodysplastic Syndromes in Older Patients

Target Audience and Goal Statement

Disclosures

Author(s)

Frederick R. Appelbaum, MD

Stephen J. Forman, MD

Gail J. Roboz, MD

David Steensma, MD

Willis Navarro, MD

Editor(s)

Charlotte Warren

Ellyce Hayes

Alissa Salvato

Tim Walker

CME Reviewer(s)

Nafeez Zawahir, MD

Accreditation Statements

For Physicians

Instructions for Participation and Credit

Acute Myeloid Leukemia and Myelodysplastic Syndromes in Older Patients

Abbreviations